UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000058451 |
|---|---|
| Receipt number | R000066834 |
| Scientific Title | A Retrospective Cohort Study of Behavior Change Prediction and Glycemic Control Using a Combined 50 kHz Reactance and Neighborhood Walking Environment Score in Newly Diagnosed Type 2 Diabetes Mellitus Patients |
| Date of disclosure of the study information | 2025/07/14 |
| Last modified on | 2025/07/14 04:30:09 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Retrospective Cohort Study of Behavior Change Prediction and Glycemic Control Using a Combined 50 kHz Reactance and Neighborhood Walking Environment Score in Newly Diagnosed Type 2 Diabetes Mellitus Patients
Acronym
A Retrospective Cohort Study of Behavior Change Prediction and Glycemic Control Using a Combined 50 kHz Reactance and Neighborhood Walking Environment Score in Newly Diagnosed Type 2 Diabetes Mellitus Patients
Scientific Title
A Retrospective Cohort Study of Behavior Change Prediction and Glycemic Control Using a Combined 50 kHz Reactance and Neighborhood Walking Environment Score in Newly Diagnosed Type 2 Diabetes Mellitus Patients
Scientific Title:Acronym
A Retrospective Cohort Study of Behavior Change Prediction and Glycemic Control Using a Combined 50 kHz Reactance and Neighborhood Walking Environment Score in Newly Diagnosed Type 2 Diabetes Mellitus Patients
Region
| Japan |
Condition
Condition
Type 2 diabetes
Classification by specialty
| Endocrinology and Metabolism | Not applicable |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To develop and validate a synergistic behavioral prediction index (SBPI) combining 50 kHz reactance and neighborhood walking environment scores in newly diagnosed type 2 diabetic patients to assess its predictive accuracy for successful behavior change and achievement of glycemic control in lifestyle interventions.
Basic objectives2
Others
Basic objectives -Others
Evaluation of the ability of bioelectrical impedance-derived body composition indices to predict independently Analysis of the effect-modifying effect of environmental factors (walking environment) Verification of improved prediction accuracy by insulin resistance stratification Estimation of effect after adjustment for selection bias using causal inference methods Creation of feature importance rankings using machine learning
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Assessment
Primary outcomes
Achieved good glycemic control (HbA1c <7.0%) after 4 months
Key secondary outcomes
HbA1c change Body composition change (50 kHz reactance, muscle mass, body fat percentage) Muscle strength index change Composite body composition index change Intervention adherence
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Food | Behavior,custom | Other |
Interventions/Control_1
Standardized Lifestyle Intervention (diet + exercise + education) Intervention arm description: 4-month structured lifestyle intervention program for newly diagnosed type 2 diabetes patients with routine body composition measurements at initial visit and every 2 months
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Newly diagnosed type 2 diabetes (within 3 months of diagnosis) Age 20-80 Baseline HbA1c 6.5-9.9% (48-85 mmol/mol) Available to participate in lifestyle intervention
Key exclusion criteria
Type 1 diabetes or secondary diabetes Pregnant or lactating Serious liver disease (ALT >3 times upper limit of normal) Heart failure (NYHA Class III-IV) Dialysis or eGFR <30 mL/min/1.73m^2 Contraindication to bioelectrical impedance measurement Not obtain informed consent
Target sample size
195
Research contact person
Name of lead principal investigator
| 1st name | Akira |
| Middle name | |
| Last name | Kimura |
Organization
Gunma Paz University
Division name
Department of Rehabilitation Sciences
Zip code
3700006
Address
Tonyamachi1-7-1,Takasaki,Gunma, Japan
TEL
027-365-3366
kimuaki@nifty.com
Public contact
Name of contact person
| 1st name | Akira |
| Middle name | |
| Last name | Kimura |
Organization
Gunma Paz University
Division name
Department of Rehabilitation Sciences
Zip code
3700006
Address
1-7-1 Tonyamachi,Takasaki,Gunma
TEL
027-365-3366
Homepage URL
https://kimuakilabo.main.jp/UMIN-CTR-Study2023-1
kimuaki@nifty.com
Sponsor or person
Institute
Gunma Paz University
Institute
Department
Personal name
Akira Kimura
Funding Source
Organization
Gunma Paz University
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Saiseikai Maebashi Hospital
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Gunma Paz University
Address
1-7-1 Tonyamchi, Takasaki, Gunma
Tel
027-365-3366
kimuaki@nifty.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
群馬県
Institutions
Institutions
済生会前橋病院（群馬県）
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 07 | Month | 14 | Day |
Related information
URL releasing protocol
https://kimuakilabo.main.jp/kaken2024-2026-1
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
195
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2023 | Year | 06 | Month | 21 | Day |
Date of IRB
| 2023 | Year | 06 | Month | 20 | Day |
Anticipated trial start date
| 2023 | Year | 06 | Month | 21 | Day |
Last follow-up date
| 2024 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
| 2025 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2025 | Year | 04 | Month | 01 | Day |
Date analysis concluded
| 2025 | Year | 07 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2025 | Year | 07 | Month | 14 | Day |
Last modified on
| 2025 | Year | 07 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066834
